HER2-negative Breast Cancer Clinical Trials in Boston, Massachusetts

10 studies are recruiting for her2-negative breast cancer in Boston, Massachusetts right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

   The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, toler…

   Stage

   Phase 1

   Ages

   12 and older

   Site

   Massachusetts General Hospital, Boston, Massachusetts

   Locations

   77 in total

   Run by

   PMV Pharmaceuticals, Inc

   See if you can join NCT04585750 on ClinicalTrials.gov

2. Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

   This is a global, multicenter, open-label, randomized Phase 3 study comparing the efficacy and safety of RLY-2608 (zovegalisib) + fulvestrant to capivasertib + fulvestrant for the treatment of patients with HR+/HER2- ABC with PIK3CA mutation following recurrence or progression on or after treatment…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Tufts Medical Center, Boston, Massachusetts

   Locations

   231 in total

   Run by

   Relay Therapeutics, Inc.

   See if you can join NCT06982521 on ClinicalTrials.gov

3. Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer

   This research is being done to evaluate the safety and tolerability of the new drug, axatilimab, in combination with olaparib (a standard of care treatment) in Breast Cancer 1/2 genes (BRCA 1/2) and PALB2 associated HER2-negative metastatic breast cancer. The names of the study drugs involved in th…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Dana-Farber Cancer Institute, Boston, Massachusetts

   Locations

   2 in total

   Run by

   Dana-Farber Cancer Institute

   See if you can join NCT06488378 on ClinicalTrials.gov

4. TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd

   The purpose of this study is to test the safety and effectiveness of the sequence of two investigational drugs (trastuzumab deruxtecan followed by datopotamab deruxtecan, or datopotamab deruxtecan followed by trastuzumab deruxtecan) to learn whether the treatment works in treating HER2-negative (HE…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Dana-Farber Cancer Institute, Boston, Massachusetts

   Locations

   11 in total

   Run by

   Ana C Garrido-Castro, MD

   See if you can join NCT06533826 on ClinicalTrials.gov

5. DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs

   The purpose of this study is to test the safety and effectiveness of the study drug datopotamab deruxtecan in participants with metastatic breast cancer that has spread to the brain. The name of the study drug used in this research study is: Datopotamab deruxtecan (a type of antibody-drug conjugate)

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Dana-Farber Cancer Institute, Boston, Massachusetts

   Locations

   3 in total

   Run by

   Nancy Lin, MD

   See if you can join NCT06176261 on ClinicalTrials.gov

6. Sacituzumab Govitecan In TNBC

   This research study is studying to evaluate sacituzumab govitecan for individuals with localized triple negative breast cancer (TNBC) The names of the study drugs involved in this study is: * Sacituzumab govitecan (SG) * Pembrolizumab (combination therapy with SG)

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Dana Farber Cancer Institute, Boston, Massachusetts

   Locations

   5 in total

   Run by

   Massachusetts General Hospital

   See if you can join NCT04230109 on ClinicalTrials.gov

7. Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer

   This is an open label, multicenter, single arm phase II study to evaluate the efficacy and safety of ribociclib and ET in patients with locoregional recurrence of HR-positive, HER2-negative breast cancer.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Tufts Medical Center, Boston, Massachusetts

   Locations

   21 in total

   Run by

   Oana Danciu

   See if you can join NCT05467891 on ClinicalTrials.gov

8. ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer

   The goal of this study is to evaluate the safety and efficacy of elacestrant in combination with trastuzumab deruxtecan (T-DXd) in participants with hormone receptor-positive (HR+), HER2-low or HER2-ultralow, metastatic breast cancer that is resistant to prior CDK4/6 inhibitor and endocrine therapy…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Dana-Farber Cancer Institute, Boston, Massachusetts

   Run by

   Kristina A. Fanucci

   See if you can join NCT07198724 on ClinicalTrials.gov

9. SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells

   The clinical trial is a phase 1, single-arm trial that will evaluate the safety of the investigational treatment on metastatic pancreatic cancer and metastatic breast cancer. The investigational treatment will involve 2 cycles of a combination of intravenous melphalan, BCNU, vitamin B12b, and vitam…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Massachusetts General Hospital, Boston, Massachusetts

   Locations

   2 in total

   Run by

   General Oncology, Inc.

   See if you can join NCT04150042 on ClinicalTrials.gov

10. First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

    This is an open-label, FIH study designed to evaluate the maximum tolerated dose, recommended Phase 2 dose, safety, tolerability, PK, pharmacodynamics, and preliminary antineoplastic activity of RLY-2608, in advanced solid tumor patients with a Phosphatidylinositol-4,5-bisphosphate-3 kinase, cataly…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Massachusetts General Hospital, Boston, Massachusetts

    Locations

    37 in total

    Run by

    Relay Therapeutics, Inc.

    See if you can join NCT05216432 on ClinicalTrials.gov